Document Detail

Microvascular density of breast cancer in bone metastasis: influence of therapy.
MedLine Citation:
PMID:  16080568     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Bone is the most frequent site of systemic progression of breast cancer (BRC). Angiosuppressive therapy has now entered the management of progressing cancers, therefore it is clinically important to obtain information on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of bone metastasis of BRC. MATERIALS AND METHODS: VEGF expression and MVD were evaluated in bone metastases of BRC immunohistochemically in paraffin samples of 18 patients and compared to their primary tumors. MVD was determined by using the hot-spot method and the endothelial marker, CD34. RESULTS: Chemo- and/or endocrine therapy-naïve BRC cases progressed to the bone with a concomitant increase in their angiogenic potential, suggesting that this is the "natural history" of BRC progression. On the other hand, this study revealed that vascularization of the bone metastases of BRC patients that had received adjuvant (chemo- and/or endocrine) therapy was significantly decreased compared to the corresponding primary tumors, also supported by a decreased VEGF expression in metastases, both suggesting that the treatment significantly affected the angiogenic phenotype of the progressing disease. CONCLUSION: Angiosuppressive therapy is a new approach to cancer management including BRC and is frequently applied in the advanced stage of disease. Tumors with a prominent angiogenic phenotype (high MVD and VEGF) are primary candidates for such regimes. The fact that chemo-endocrine adjuvant therapy of BRC resulted in a weaker angiogenic phenotype in bone metastases compared to non-treated cases may suggest that these latter patients are better candidates for angiosuppressive interventions.
Támas Lörincz; József Tóth; Miklós Szendröi; József Tímár
Related Documents :
21541018 - Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate c...
17873108 - Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prev...
17556308 - An overview of the pathophysiology of vascular calcification in chronic kidney disease.
11405448 - Mandibular invasion of lower gingival carcinoma in the molar region: its clinical impli...
23333058 - Mir-17-5p/20a are important markers for gastric cancer and murine double minute 2 parti...
20569478 - "if you don't believe it, it won't help you": use of bush medicine in treating cancer a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  25     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2005 Jul-Aug
Date Detail:
Created Date:  2005-08-05     Completed Date:  2005-09-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3075-81     Citation Subset:  IM    
Department of Orthopedics, Semmelweis University, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Neoplasms / blood supply*,  metabolism,  secondary*,  therapy
Breast Neoplasms / metabolism,  pathology*,  therapy*
Breast Neoplasms, Male / metabolism,  pathology
Carcinoma, Ductal / blood supply,  metabolism,  secondary,  therapy
Cohort Studies
Middle Aged
Neovascularization, Pathologic / metabolism,  pathology
Retrospective Studies
Vascular Endothelial Growth Factor A / biosynthesis
Reg. No./Substance:
0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatocellular carcinoma in hepatectomized patients: biologic and therapeutic implications.
Next Document:  Nuclear area is a prognostic determinant in advanced colorectal cancer.